ValuEngine Lowers Becton Dickinson and (NYSE:BDX) to Hold

ValuEngine lowered shares of Becton Dickinson and (NYSE:BDX) from a buy rating to a hold rating in a report issued on Thursday morning, ValuEngine reports.

Other equities analysts have also issued reports about the company. Morgan Stanley raised their price target on Becton Dickinson and from $250.00 to $261.00 and gave the stock an equal weight rating in a report on Tuesday, July 16th. Barclays raised Becton Dickinson and from an equal weight rating to an overweight rating and set a $266.00 price target for the company in a report on Monday, May 13th. UBS Group cut their price target on Becton Dickinson and from $265.00 to $250.00 and set a neutral rating for the company in a report on Friday, May 10th. Zacks Investment Research raised Becton Dickinson and from a sell rating to a hold rating in a report on Monday, May 20th. Finally, BMO Capital Markets cut their price target on Becton Dickinson and from $272.00 to $270.00 and set a market perform rating for the company in a report on Friday, May 10th. Six equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Becton Dickinson and currently has a consensus rating of Buy and an average target price of $263.58.

Shares of Becton Dickinson and stock traded down $3.66 during trading hours on Thursday, reaching $248.69. The company had a trading volume of 1,166,959 shares, compared to its average volume of 766,165. Becton Dickinson and has a one year low of $208.62 and a one year high of $265.87. The business has a fifty day moving average price of $250.17. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.59 and a current ratio of 0.96. The company has a market cap of $68.19 billion, a price-to-earnings ratio of 22.59, a PEG ratio of 1.87 and a beta of 1.11.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $2.59 EPS for the quarter, topping the Zacks’ consensus estimate of $2.57 by $0.02. Becton Dickinson and had a return on equity of 14.58% and a net margin of 5.88%. The firm had revenue of $4.20 billion during the quarter, compared to analyst estimates of $4.25 billion. During the same period last year, the company earned $2.65 earnings per share. The business’s revenue for the quarter was down .6% on a year-over-year basis. As a group, equities research analysts predict that Becton Dickinson and will post 11.68 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 1.24%. The ex-dividend date is Friday, September 6th. Becton Dickinson and’s dividend payout ratio is 27.97%.

In related news, EVP Samrat S. Khichi sold 16,085 shares of Becton Dickinson and stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $234.68, for a total transaction of $3,774,827.80. Following the completion of the sale, the executive vice president now owns 12,608 shares of the company’s stock, valued at $2,958,845.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Betty D. Larson sold 1,700 shares of Becton Dickinson and stock in a transaction on Monday, May 13th. The shares were sold at an average price of $224.97, for a total value of $382,449.00. Following the sale, the executive vice president now directly owns 11,493 shares of the company’s stock, valued at approximately $2,585,580.21. The disclosure for this sale can be found here. Insiders have sold 21,154 shares of company stock valued at $4,955,775 in the last three months. 0.12% of the stock is owned by corporate insiders.

A number of large investors have recently bought and sold shares of the stock. Whittier Trust Co. lifted its stake in Becton Dickinson and by 0.6% during the second quarter. Whittier Trust Co. now owns 6,982 shares of the medical instruments supplier’s stock worth $1,760,000 after purchasing an additional 40 shares during the last quarter. Ropes Wealth Advisors LLC lifted its stake in Becton Dickinson and by 0.6% during the second quarter. Ropes Wealth Advisors LLC now owns 6,801 shares of the medical instruments supplier’s stock worth $1,714,000 after purchasing an additional 43 shares during the last quarter. Ballentine Partners LLC lifted its stake in Becton Dickinson and by 2.3% during the first quarter. Ballentine Partners LLC now owns 2,232 shares of the medical instruments supplier’s stock worth $558,000 after purchasing an additional 50 shares during the last quarter. Private Asset Management Inc. lifted its stake in Becton Dickinson and by 2.0% during the second quarter. Private Asset Management Inc. now owns 2,532 shares of the medical instruments supplier’s stock worth $638,000 after purchasing an additional 50 shares during the last quarter. Finally, Community Bank & Trust Waco Texas lifted its stake in Becton Dickinson and by 1.8% during the second quarter. Community Bank & Trust Waco Texas now owns 2,754 shares of the medical instruments supplier’s stock worth $694,000 after purchasing an additional 50 shares during the last quarter. 84.80% of the stock is owned by institutional investors.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Read More: What is systematic risk?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.